biostudies-literatureUnknown11Nuzzo F<h4>Background</h4>To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly ones in terms of quality of life in locally advanced or metastatic breast cancer.<h4>Methods</h4>Patients with locally advanced or metastatic breast cancer, aged ≤ 70 years, performance status 0-2, chemotherapy-naive for metastatic disease, were eligible. They were randomized to weekly or 3-weekly combination of docetaxel and epirubicin, if they were not treated with adjuvant anthracyclines, or docetaxel and capecitabine, if treated with adjuvant anthracyclines. Primary end-point was global quality of life change at 6-weeks, measured by EORTC QLQ-C30. With two-sided alpha 0.05 and 80% power for 35% effect size, 130 patients per arm were needed.<h4>Results</h4>From February 2004BMC cancer75https://www.ebi.ac.uk/biostudies/studies/S-EPMC3050853biostudies-literatureEffects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.PMC3050853Perrone FRinaldo MRossi EDe Maio Ede Matteis AD'Aiuto GGravina AMorabito ADi Bonito MDi Rella FPiccirillo MCNuzzo FPacilio CLabonia VThomas RLandi GBotti GGallo CDi Maio MfalseEffects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.<h4>Background</h4>To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly ones in terms of quality of life in locally advanced or metastatic breast cancer.<h4>Methods</h4>Patients with locally advanced or metastatic breast cancer, aged ≤ 70 years, performance status 0-2, chemotherapy-naive for metastatic disease, were eligible. They were randomized to weekly or 3-weekly combination of docetaxel and epirubicin, if they were not treated with adjuvant anthracyclines, or docetaxel and capecitabine, if treated with adjuvant anthracyclines. Primary end-point was global quality of life change at 6-weeks, measured by EORTC QLQ-C30. With two-sided alpha 0.05 and 80% power for 35% effect size, 130 patients per arm were needed.<h4>Results</h4>From February 20042011-01-01T00:00:00Z2011 Feb2026-04-07T21:56:38.192Z2026-04-07T18:19:48.34ZS-EPMC30508532132418410.1186/1471-2407-11-75